About Sumitomo Pharma R&D Capabilities

The Psychiatry & Neurology Area is a disease area with high unmet medical needs and a significant impact on healthy life expectancy. We have a rich track record and expertise in the research and development of numerous products over the years. In addition to the drug discovery of small molecule, we are also challenging new modalities such as Regenerative Medicine/Cell Therapy Business and Frontier Business.

We are engaged in drug discovery using advanced technologies (in silico, biomarkers, iPS cells, etc.), on the strength of our experience with continuous product creation and our R&D know-how. We conduct competitive drug discovery research based on our proprietary drug discovery technology platform, which we have built by incorporating cutting-edge technologies.

This is a field with great market potential due to our ability to take advantage of the accumulated research and comprehensive capabilities built up by Sumitomo Pharma Group over many years, and to approach the treatment of diseases that cannot be solved by existing therapeutic agents.

Our Group aims to provide new value in the regenerative and cell medicine field by leveraging our strengths in networking through open innovation with academia, startup companies, and other industries. We utilize our accumulated technologies for the practical application of iPS cells, such as differentiation induction technology from pluripotent stem cells, and our extensive manufacturing capabilities, methods, infrastructure, and human resources related to cell production. Specifically, we plan to expand our therapeutic areas from the central nervous system and ophthalmology fields to peripheral organs, enter overseas markets with Japan as a base, and transition from supplying single cells to providing 3D tissues and organs.